In Vitro Diagnostics (IVD) Market.png
Global In Vitro Diagnostics (IVD) Market to Generate USD 118.57 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
August 19, 2022 09:03 ET | Next Move Strategy Consulting
New York, Aug. 19, 2022 (GLOBE NEWSWIRE) -- According to the report published by Next Move Strategy Consulting, the global in vitro diagnostics (IVD) market generated USD 86.51 billion in 2021, and...
TIP_link_300x300.jpg
Companion Animal Diagnostics Market Revenue to Cross $2.68Bn, Globally, by 2027 at 4.1% CAGR – Exclusive Report by The Insight Partners
July 28, 2022 09:30 ET | The Insight Partners
New York, July 28, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Companion Animal Diagnostics Market Forecast to 2027 - Covid-19 Impact and Global Analysis by...
ADPT new logo.jpg
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
July 28, 2022 07:30 ET | Adaptive Biotechnologies
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes
June 12, 2022 10:00 ET | MDS Foundation, Inc. (963786)
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk...
Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
June 09, 2022 04:49 ET | BTG Specialty Pharmaceuticals
Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion...
Aptose Biosciences Inc. logo
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 20:10 ET | Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 ...
Aptose Biosciences Inc. logo
Aptose Presents Highlights from Corporate Update and KOL Event
June 02, 2022 17:30 ET | Aptose Biosciences, Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02, 2022 (GLOBE...
ADPT new logo.jpg
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology
June 02, 2022 16:10 ET | Adaptive Biotechnologies
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...
Meticulous Logo.png
Veterinary Point-of-Care Diagnostics Market Worth $2.32 Billion by 2029 - Exclusive Report by Meticulous Research®
May 23, 2022 10:00 ET | Meticulous Market Research Pvt. Ltd.
Redding, California, May 23, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Veterinary PoC Diagnostics Market by Product (Kits & Reagents, Analyzers), Technology...
PRPO logo.png
Precipio Signs First IV-Cell Customer Agreement
May 10, 2022 10:30 ET | Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...